Category Archives: Compulsory Licensing

Eli Lilly’s ISDS Patent Claim against Canada Defeated

In an unprecedented case, Eli Lilly initiated an amended investor-state-dispute-settlement (ISDS) claim against the government of Canada in 2013 after Canada’s highest courts upheld invalidations on new therapeutic use patents for two chemical compounds – olanzapine and atomoxetine, the active … Continue reading

Posted in Compulsory Licensing, FTA, Investor state dispute, Uncategorized | Leave a comment

Compulsory licensing required for essential drugs: Y K Hamied

Pragmatic compulsory licensing policy is needed to enable India to look after health of its people as it cannot afford monopoly in healthcare with the challenges it faces, Cipla’s Y K Hamied said.

Posted in Compulsory Licensing, Uncategorized | Leave a comment

How charity is fuelling a superbug in India?

By Ruhi Khandar, The Ken The evil superbug is on the lookout for new hosts. The hero has the weapon, he can conquer it, but only if he is willing. The superbug is antibiotic-resistant bacteria, which causes multi-drug-resistant tuberculosis (MDR-TB), the … Continue reading

Posted in Compulsory Licensing, Drugs, Tuberculosis (TB), Uncategorized | Tagged , , | Leave a comment

It’s Official: TRIPS Health Amendment In Effect, First Ever To A WTO Agreement

Source: More than a decade after World Trade Organization member states approved the first-ever legal amendment to a WTO agreement, the change to the international intellectual property agreement has entered into effect. Five more members ratified the amendment in … Continue reading

Posted in Compulsory Licensing, Doha Declaration, TRIPS, TRIPS flexibilities, Uncategorized, WTO | Leave a comment

India to US: Will not tighten IPR rules beyond TRIPS mandate

Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report | Leave a comment

Doctors push Italy to demand generics for pricey hep c drugs

By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS, Uncategorized | Leave a comment

PhRMA slams Colombian efforts to cut price of cancer drug

By Suzanne Elvidge, BioPharma Dive| Sept 15, 2016 Dive Brief: Major trade organization PhRMA sharply criticized a decision by the Colombian government to reduce the price of Novartis’ cancer drug Gleevec (imatinib) in the country, calling the move a “harmful global precedent” … Continue reading

Posted in Compulsory Licensing, Drug prices, TRIPS plus, Uncategorized | Leave a comment